Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar:6:414-438.
doi: 10.1200/JGO.19.00367.

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

Affiliations

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

E Gabriela Chiorean et al. JCO Glob Oncol. 2020 Mar.

Abstract

Purpose: To provide expert guidance to clinicians and policymakers in resource-constrained settings on the management of patients with late-stage colorectal cancer.

Methods: ASCO convened a multidisciplinary, multinational Expert Panel that reviewed existing guidelines, conducted a modified ADAPTE process, and used a formal consensus process with additional experts for two rounds of formal ratings.

Results: Existing sets of guidelines from four guideline developers were identified and reviewed; adapted recommendations from five guidelines form the evidence base and provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75% on all recommendations.

Recommendations: Common elements of symptom management include addressing clinically acute situations. Diagnosis should involve the primary tumor and, in some cases, endoscopy, and staging should involve digital rectal exam and/or imaging, depending on resources available. Most patients receive treatment with chemotherapy, where chemotherapy is available. If, after a period of chemotherapy, patients become candidates for surgical resection with curative intent of both primary tumor and liver or lung metastatic lesions on the basis of evaluation in multidisciplinary tumor boards, the guidelines recommend patients undergo surgery in centers of expertise if possible. On-treatment surveillance includes a combination of taking medical history, performing physical examinations, blood work, and imaging; specifics, including frequency, depend on resource-based setting.Additional information is available at www.asco.org/resource-stratified-guidelines.

PubMed Disclaimer

Conflict of interest statement

E. Gabriela Chiorean

Consulting or Advisory Role: Celgene, Five Prime Therapeutics, Halozyme, Vicus Therapeutics, Ipsen, AstraZeneca, Eisai, Seattle Genetics, Array BioPharma

Research Funding: Celgene (Inst), Incyte (Inst), Stemline Therapeutics (Inst), Ignyta (Inst), Boehringer Ingelheim (Inst), Lilly (Inst), Merck (Inst), Halozyme (Inst), MacroGenics (Inst), Rafael Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), AADi (Inst)

Travel, Accommodations, Expenses: AstraZeneca, Seattle Genetics

Govind Nandakumar

Speakers' Bureau: Medtronic

Suyapa Bejarano

Research Funding: MSD Oncology, Kinex

Travel, Accommodations, Expenses: Pfizer, Asofarma

Adina-Emilia Croitoru

Consulting or Advisory Role: Lilly, Merck Serono, Roche, Bayer, Novartis, Sandoz, Ipsen

Research Funding: Gilead Sciences, Pfizer, Can-Fite BioPharma, NanoCarrier, Bristol-Myers Squibb, Gilead Sciences (Inst), Pfizer (Inst), Can-Fite BioPharma (Inst), NanoCarrier (Inst), Bristol-Myers Squibb (Inst), Merck KGaA, Merck KGaA (Inst), SERVIER, SERVIER (Inst), Amgen, Five Prime Therapeutics, Five Prime Therapeutics (Inst)

Travel, Accommodations, Expenses: Pfizer, Genekor, Sandoz, Merck, SERVIER

Andrew Odhiambo

Honoraria: Novartis, AstraZeneca, Roche

Consulting or Advisory Role: AstraZeneca

Travel, Accommodations, Expenses: AstraZeneca, Janssen, Beacon Medicare, Merck

Se Hoon Park

Honoraria: Merck Sharp & Dohme, Sanofi/Aventis

Consulting or Advisory Role: Lilly, Janssen Oncology

Research Funding: Kura Oncology, Ono Pharmaceutical

Erika Ruiz Garcia

Travel, Accommodations, Expenses: Amgen, Merck Serono, MSD

Bassem Zaki

Research Funding: Immunomedics (Inst)

Mary D. Chamberlin

Consulting or Advisory Role: Genomic Health International

Research Funding: Archer Biosciences (Inst)

No other potential conflicts of interest were reported.

Similar articles

Cited by

References

    1. International Agency for Research on Cancer Cancer Fact Sheets: Colorectal Cancerhttp://gco.iarc.fr/today/fact-sheets-cancers?cancer=6&type=0&sex=0
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Anderson BO, Shyyan R, Eniu A, et al. Breast cancer in limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. Breast J. 2006;12(s) uppl 1:S3–S15. - PubMed
    1. Horton S, Gauvreau CL: Cancer in low- and middle-income countries: An economic overview, in Gelband H, Jha P, Sankaranarayanan R, et al (eds): Cancer: Disease Control Priorities, Volume 3 (ed 3). Washington, DC, The International Bank for Reconstruction and Development/The World Bank, 2015. - PubMed
    1. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308–1311. - PubMed